Olema Pharmaceuticals, Inc. OLMA Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Olema Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Olema Pharmaceuticals, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Olema Pharmaceuticals, Inc.'s operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Olema Pharmaceuticals, Inc.'s operating lease right-of-use asset amortization?
- Olema Pharmaceuticals, Inc. (OLMA) reported operating lease right-of-use asset amortization of $301K in Q1 2026.
- How has Olema Pharmaceuticals, Inc.'s operating lease right-of-use asset amortization changed year-over-year?
- Olema Pharmaceuticals, Inc.'s operating lease right-of-use asset amortization increased by 4.9% year-over-year, from $287K to $301K.
- What is the long-term trend for Olema Pharmaceuticals, Inc.'s operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), Olema Pharmaceuticals, Inc.'s operating lease right-of-use asset amortization has grown at a -1.0% compound annual growth rate (CAGR), from $1.22M to $1.18M.